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Abstract
Background. We initiated a randomized controlled clinical
trial to assess the effect of sirolimus on disease progres-
sion in patients affected by autosomal dominant polycystic
kidney disease (ADPKD). Here we report the preliminary
safety results of the first 6 months of treatment.
Method. A total of 25 patients were randomized to
sirolimus 2 mg/day and 25 patients to no treatment ex-
cept standard care. Treatment adherence was monitored
electronically. At baseline and at Month 6, laboratory pa-
rameters were analysed and the urinary protein profile in
24-h urine collections was determined.
Results. Both treatment groups were well balanced for age,
sex and renal function. In 94.1 ± 11.4% of the study days,
patients in the sirolimus group were exposed to the drug
when assuming a therapeutic efficacy duration of 30 h.
At Month 6, the mean sirolimus dose and trough level
were 1.28 ± 0.71 mg/day and 3.8 ± 1.9 µg/l, respec-
tively. Glomerular (albumin, transferrin, IgG) and tubular
(retinol-binding protein, α1-microglobulin) protein excre-
tion remained unchanged. Glomerular filtration rate also
did not change significantly. Haematological parameters
were similar in both groups, except for a mild reduction
of the mean corpuscular volume of erythrocytes in pa-
tients receiving sirolimus. Lipid levels were similar in both
groups. Adverse events were transient and mild, and no
grade 3 or 4 events occurred. The incidence of infections
was similar in the sirolimus group (80%) and the standard
group (88%). The most common gastrointestinal adverse
events were mucositis (72% in the sirolimus group versus
16% in the standard group, P = 0.0001) and diarrhoea
(36% in the sirolimus versus 20% in the standard group,
P = 0.345).
Conclusion. Treatment of ADPKD patients with sirolimus
with a dose of 1–2 mg/day is safe and does not cause pro-
teinuria or impairment of GFR. Treatment adherence was
excellent. (ClinicalTrials.gov number, NCT00346918.)
Keywords: autosomal dominant polycystic kidney disease (ADPKD);
safety; sirolimus; treatment adherence; urinary protein profile
Introduction
Autosomal dominant polycystic kidney disease (ADPKD)
represents the most frequent potentially lethal monogenic
hereditary disease of mankind [1]. The estimated number
of cases in Europe and in the United States amounts to
700 000 and 300 000, respectively. The relentless develop-
ment and growth of innumerable cysts lead to progressive
destruction of the normal renal parenchyma and massive
enlargement of the kidneys. Subsequently, the glomerular
filtration rate decreases in an accelerated mode, and end-
stage renal disease with the need for dialysis and/or trans-
plantation ensues. Data from the consortium for radiologic
imaging studies of polycystic kidney disease (CRISP) have
shown that the rate of kidney volume growth is an excellent
predictor of renal functional decline [2]. Therefore, kidney
volume growth can be used as a surrogate marker of dis-
ease progression [3]. Despite decades of intense basic and
clinical research, effective treatment that alters the course
of ADPKD has not been established.
Sirolimus, also termed rapamycin, is an immunosuppres-
sant that binds to FK-binding protein-12 (FKBP-12) and
inhibits the activation of mTOR, a key regulatory kinase of
growth and proliferation [4]. We and others have previously
shown that the mTOR inhibitors sirolimus and everolimus
effectively reduce cyst growth and loss of renal function in
an experimental animal model for polycystic kidney disease
(PKD) [5–7]. Additional studies have shown that sirolimus
is also effective in various mouse models of PKD, includ-
ing dominant and recessive forms [8]. Of interest, analyses
of ADPKD patients that received a renal allograft revealed
that cystic kidney and liver volumes regressed under im-
munosuppression with sirolimus [8,9].
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Based on these encouraging studies, we have initiated a
randomized controlled clinical trial as a proof-of-concept
study to examine the effect of sirolimus on cyst volume
growth in young patients with documented ADPKD and
normal GFR [10]. Here we report the preliminary safety
and tolerability results of this clinical trial, with particular
emphasis on the effect of sirolimus on proteinuria and GFR.
Methods
Patient population and study design
The SUISSE ADPKD study represents an ongoing single-centre, prospec-
tive, open-label, randomized controlled clinical trial to assess the efficacy
of sirolimus (Rapamune R©, Wyeth AG, Zug, Switzerland) to decrease re-
nal volume enlargement in patients with ADPKD. The study involves 100
ADPKD patients aged 18–40 years with an estimated creatinine clearance
>70 ml/min. Prior to randomization, polycystic kidneys are visualized by
MRI without contrast media within an interval of 6 months, and kidney
and cyst volumes are measured by volumetry. The volumetry method has
been previously validated and showed an excellent reliability [3]. Patients
with documented total kidney volume (TKV) enlargement of >2% are
randomized at a one-to-one ratio of sirolimus 2 mg/day or standard care
for 18 months. At the discretion of the treating physician, the starting dose
was reduced to 1 mg in case of anticipated sirolimus-associated toxicity.
An independent biostatistics unit generated the randomization list, using
a permuted block design with a random block size of 4 or 6 to guarantee
a balanced allocation. Patients in the standard arm had visits at Months
3 and 6, and patients in the sirolimus arm had four extra visits at Weeks
2 and 4 and Months 1 and 2 after randomization to allow for blood level
monitoring and dose adjustments. The sirolimus dose was reduced or
withheld when the trough level exceeded 10 µg/l, or when elevated liver
enzymes (>2-fold above normal values), thrombopenia (<100 000/mm3)
and leukopenia (<3000/mm3) occurred. Standard care included blood
pressure control and symptomatic treatment of flank pain, cyst bleedings
and cyst infections.
The study was approved by the institutional review board, conducted
according to Good Clinical Practice guidelines and the Declaration of
Helsinki and controlled by external monitoring. All participants gave
written informed consent. Details of the study design have been reported
elsewhere [10]. Briefly, from a local prospective ADPKD cohort, we se-
lected 100 patients with documented TKV progression for inclusion (i.e.
randomization) in the trial. Approximately 80% of patients considered for
randomization had ≥2% TKV progression within an interval of 6 months
(data not shown). According to a predefined interim analysis plan, the
first 50 patients that had completed 6 months of sirolimus treatment (n =
25) or standard care (n = 25) were subjected to a safety and tolerability
analysis. The entire study is powered to enrol a total of 100 patients and
to continue until there is a mean 18-month follow-up. Here we report on
the first 50 randomized patients, focusing particularly on the safety and
tolerability of sirolimus treatment.
Study procedures
A detailed medical history was obtained from all patients, including
ADPKD-related symptoms, previous hospitalizations and medication.
Blood pressures were measured twice 5 min apart in each arm in the
sitting position after a rest of 5 min, using an oscillometric blood pressure
monitor (Boso-Medicus, Jungingen, Germany) at each visit. The lower of
the two consecutive measurements in the arm with the higher blood pres-
sure was used for analysis. Arterial hypertension was defined as systolic
blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg on
two or more study visits, or treatment with an antihypertensive drug.
Adherence to the prescribed study drug was assessed during the en-
tire treatment period by an electronic system that monitors the date
and time of the medication bottle opening (MEMS R©, Aardex Ltd, Zug,
Switzerland). This electronic system reliably assesses medication adher-
ence as a period with a lack of medication bottle opening, which was
considered to represent an episode of non-adherence [11,12]. The per-
centage of time when the patient was exposed to the drug action was
calculated based on two different estimates of duration of therapeutic ef-
ficacy of sirolimus, namely 24 h plus 6 h (6-h forgetfulness period) and
24 h plus 24 h (24-h forgetfulness period).
Laboratory analyses
Blood was obtained for the determination of creatinine (IDMS-traceable
modified Jaffe´ method), lipids, liver enzymes and haematologic parame-
ters including erythrocyte indices. Trough levels of sirolimus were deter-
mined by liquid chromatography—mass spectrometry in samples of whole
blood.
Twenty-four-hour urine samples were collected at baseline and at
Month 6. Aliquots of these urine samples were centrifuged at 1500 g
for 5 min, and the supernatants were stored at −80◦C prior to analysis.
Albumin, transferrin and immunoglobulin G (IgG) were analysed as uri-
nary markers of glomerular damage, and retinol-binding protein (RBP)
and α1-microglobulin as urinary markers of tubular damage. Measure-
ment of urinary total protein (benzethonium chloride method, Roche Ltd,
Basel, Switzerland) and serum creatinine (enzymatic method, Wako Pure
Chemical Industries Ltd, Osaka, Japan) were performed on a Hitachi 917
analyser, while urinary marker proteins were measured on a Beckman
Coulter nephelometry system (Beckman Coulter, Brea, USA) using anti-
bodies against albumin, transferrin, IgG and α1-microglobulin (Beckman
Coulter) and RBP (Dako, Glostrup, Denmark). The interassay coefficient
of variation was <5% for these assays. The lower limit of quantifica-
tion of the assays was 0.04 g/l for total protein, 2.0 mg/l for albumin,
0.61 mg/l for transferrin, 3.0 mg/l for IgG, 0.328 mg/l for RBP and
4.0 mg/l for α1-microglobulin [13]. The concentration values in urine
samples below the lower limit of quantification were set to zero for all
calculations.
Safety assessment
Safety was determined on the basis of the occurrence of adverse events,
findings on physical examination, and laboratory evaluations. Adverse
events affecting ≥5% in either group were described and graded accord-
ing to the National Cancer Institute (NCI) Common Terminology Criteria
for Adverse Events (CTCAE), version 3.0 [14]. A patient with multiple
occurrences of an adverse event was counted once in the corresponding
category and a patient with multiple adverse events within a primary sys-
tem organ class was also counted once for that class. Primary system organ
classes and preferred terms were sorted by the frequency of adverse events
in the total group. Safety and tolerability analyses included all randomized
patients who received at least one dose of sirolimus and underwent at least
one safety assessment.
Statistics
The results were expressed as means ± standard deviation or number of
patients (percent). For comparisons between groups, means of continuous
data were compared using Student’s t-test or the Wilcoxon rank-sum test
as appropriate and categorical data using Fisher’s exact test. All P-values
were two sided for the comparison between the groups or between base-
line and follow-up values, and those <0.05 were considered statistically
significant.
Results
Characteristics of the patients
Here we report on 50 ADPKD patients who were en-
rolled from March 2006 to March 2007 and have com-
pleted the first 6 months of the treatment. A total of 25
patients were randomly assigned to receive sirolimus and
25 patients to receive no treatment except standard care.
Table 1 shows that both treatment groups were well bal-
anced at baseline for age, sex, body mass index (BMI)
and blood pressure. Approximately 70% of patients in each
group had hypertension, mostly treated with angiotensin-
converting enzyme inhibitors (ACEi) or angiotensin re-
ceptor blockers (ARB). None of the patients were lost to
follow-up.
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Table 1. Characteristics of the patients at baselinea
Sirolimus Standard
Characteristic N = 25 N = 25 P-value
Age (years) 29 ± 6 29 ± 6 0.964
Gender, No. of male patients (%) 14 (56) 20 (80) 0.069
BMI (kg/m2) 24 ± 4 25 ± 4 0.284
Systolic blood pressure (mmHg) 131 ± 16 131 ± 15 0.985
Diastolic blood pressure (mmHg) 87 ± 11 83 ± 10 0.122
Hypertension, No. (%) 17 (68) 17 (68) 1.000
Antihypertensive treatment, No. (%)
All 10 (40) 12 (48) 0.776
ACEi and/or ARB therapy 8 (32) 11 (44) 0.561
Diuretics 2 (8) 5 (20) 0.417
Others 3 (12) 3 (12) 1.000
Symptoms and complications of
ADPKD, No. (%)
History of flank pain 6 (24) 15 (60) 0.021
History of macrohaematuria 6 (24) 6 (24) 1.000
History of cyst infections 1 (4) 3 (12) 0.609
History of intracranial bleeding 0 (0) 1 (4) 1.000
≥2 complications of ADPKD 3 (12) 4 (16) 1.000
Family history of intracranial 3 (12) 4 (16) 1.000
bleeding
aTable shows either the mean ± standard deviation or the number of
patients (percent). BMI denotes body mass index, ACEi angiotensin-
converting enzyme inhibitor and ARB angiotensin receptor blocker.
Study drug adherence
The patients in the sirolimus group were exposed to the
drug in 94.1 ± 11.4% of the study days if the duration of
therapeutic efficacy was assumed to be 30 h, or in 96.6 ±
9.7% of the days assuming a therapeutic drug action of 48 h.
The percentage of days with correct dosing was 93.0 ±
12.1%. A total of 17 patients received the correct sirolimus
dose in >95% of the study days assuming 30 h of sirolimus
therapeutic duration. The number of patients with correct
dosing at >95% of the study days amounted to 22 patients
when the therapeutic efficacy duration of sirolimus was set
to 48 h.
Sirolimus dose and whole blood trough levels
Figure 1 shows the sirolimus dose and sirolimus whole
blood trough levels. The starting dose was reduced to
1 mg/day in nine patients, mostly females (eight females,
one male), due to anticipated more severe side effects in
young female ADPKD patients. After adjustment of the
sirolimus dose in the first 2 months, the sirolimus dose,
dose per body weight and whole blood trough levels re-
mained constant and after 6 months amounted to 1.28 ±
0.71 mg/day, 0.018 ± 0.01 mg/kg/day and 3.8 ± 1.9 µg/l,
respectively.
Effect of sirolimus on renal function and urinary protein
excretion
Renal function assessed by measured and estimated crea-
tinine clearance as well as serum creatinine was similar in
the sirolimus and standard groups at baseline and at Month
6 (Table 2). Thus, sirolimus did not adversely affect GFR.
Since it is well known that sirolimus can cause protein-
uria in patients with preexisting renal disease, we exam-
ined in detail the urinary protein profile in 24 h-urine col-
lections (Table 2). The median urinary excretion of total
protein was low, and similar in both groups at baseline
(78.0 mg/day in the sirolimus group versus 65.0 mg/day in
the standard group, P= 0.077) and at Month 6 (120 mg/day
in the sirolimus group versus 86.3 mg/day in the standard
group, P = 0.087). The median urinary excretion of albu-
min was low in both groups at baseline (13.7 mg/day in the
sirolimus group versus 9.0 mg/day in the standard group,
P= 0.450) and remained low in response to sirolimus treat-
ment at Month 6 (36.0 mg/day in the sirolimus group versus
18.9 mg/day in the standard group, P = 0.349, Figure 2).
The number of patients developing microalbuminuria (as
defined by urinary albumin excretion >30 mg/24 h) during
the 6-month interval was similar in each group (+3 patients
in the sirolimus group versus +2 patients in the standard
group), and none of the patients had macroalbuminuria
(defined by urinary albumin excretion >300 mg/24 h) at
any time point. Furthermore, the urinary excretion of trans-
ferrin did not change significantly during the 6-month in-
terval. The changes in the urinary protein excretion that
occurred within the 6-month interval were similar in each
group (sirolimus versus standard mean changes of albumin
+8.4 mg/24 h, P = 0.543; transferrin +0.18 mg/mmol,
P = 0.791; and total protein −1.8 mg/24 h, P = 0.938).
IgG was detectable in four and two urine samples of the
control group and in two and seven urine samples of the
sirolimus group at baseline and at Month 6, respectively.
Fig. 1. Mean sirolimus dose (A), sirolimus dose per body weight (B) and sirolimus whole blood trough levels (C) at baseline and at follow-up visits.
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Table 2. Changes in renal function and urinary protein excretion from baseline to Month 6a
Baseline Month 6
Sirolimus Standard Sirolimus Standard
Characteristic Units Normal range N = 25 N = 25 P-value N = 25 N = 25 P-value
mCrCl (24-h urine collection) ml/min 90–120 91.7 ± 42.7 92.7 ± 46.7 0.937 110.1 ± 31.8 110.0 ± 30.7 0.996
eCrCl (Cockcroft–Gault formula) ml/min 90–120 105.1 ± 25.4 114.1 ± 23.0 0.195 109.2 ± 24.1 113.9 ± 21.7 0.474
Serum creatinine µmol/l 62–106 men 90.5 ± 18.3 95.4 ± 18.1 0.345 87.3 ± 15.7 96.2 ± 17.5 0.065
44–80 women
Urinary excretion (24-h urine collection)
Albumin, median (IQR) mg/24 h <20 13.7 (7.4–25.2) 9.0 (4.0–27.2) 0.450 36.0 (12.0–65.0) 18.9 (9.2–46.7) 0.349
Transferrin, median (IQR) mg/24 h <1.7 0.87 (0.00–3.00) 0.00 (0.00–1.84) 0.280 2.04 (1.26–3.86) 1.48 (0.00–2.63) 0.273
Total protein, median (IQR) mg/24 h <100 78.0 (60.0–123.0) 65.0 (42.0–92.0) 0.077 120.0 (84.0–175.0) 86.3 (73.9–114.0) 0.087
IgG levels above LLQ, No. (%) 2 (8) 4 (16) 7 (36) 2 (8) 0.138
RBP levels above LLQ, No. (%) 0 (0) 0 (0) 0 (0) 1 (4) 1.000
A1M levels above LLQ, No. (%) 2 (8) 3 (12) 4 (16) 6 (24) 0.715
aTable shows either the mean ± standard deviation or number of patients (percent), with the exception of urinary albumin, transferrin and total protein excretion values, which are given as medians with
interquartile range because of skewed data distribution.
mCrCl, measured creatinine clearance; eCrCl, estimated creatinine clearance; CG, Cockcroft–Gault; IQR, interquartile range; IgG, immunoglobulin G; LLQ, lower limit of quantification; RBP, retinol-binding
protein; A1M, α1, microglobulin.
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Fig. 2. The amount of albumin (A) and transferrin (B) in 24-h urine collections at Month 6. Lines represent the median and interquartile range.
Fig. 3. Mean corpuscular volume of erythrocytes (A) and red blood cell count (B) at Month 6. The lines represents the mean. Baseline mean values ±
standard deviations are shown below the x-axis.
Regarding the tubular proteins, RBP was detectable at
low concentration only in one urine sample at Month 6
and was below the lower limit of quantification in all other
samples. Likewise, α1-microglobulin was only detectable
in three and six urine samples of the standard group and
in two and four urine samples of the sirolimus group at
baseline and at Month 6, respectively. In urine samples
of 10 patients of the standard group and of 9 patients of
the sirolimus group, RBP or IgG or α1-microglobulin was
detectable at any time point of the study.
Taken together, the urinary excretion of markers for
glomerular and tubular damage remained unchanged dur-
ing the 6-month interval and was not adversely affected by
sirolimus treatment.
Effect of sirolimus on clinical and laboratory parameters
Table 3 shows that the BMI and blood pressure were simi-
lar in the sirolimus and in the standard group at Month 6.
We also analysed the influence of sirolimus on the anti-
hypertensive treatment. At baseline, 40% patients in the
sirolimus group and 48% patients in the standard group
received an antihypertensive medication, mostly ACEi or
ARB. The number of patients that started a new ACEi or
ARB treatment during the 6-month treatment phase (30%
of the sirolimus group versus 10% of the standard group)
was also similar.
Sirolimus can cause haematological alterations in renal
transplant recipients. The mean haemoglobin, mean cor-
puscular haemoglobin concentration (MCHC), and leuko-
cyte and platelet counts did not differ significantly in the
two groups of ADPKD patients (Table 3). The red blood
cell count was unchanged, whereas, the mean corpuscu-
lar volume (MCV) and the mean corpuscular haemoglobin
(MCH) were significantly lower in patients receiving
sirolimus compared to patients in the standard group
(Figure 3). Also the percentage of microcytic erythrocytes
was higher in patients on sirolimus (1.3 ± 2.3% in the
standard group versus 2.2 ± 1.3% in the sirolimus group,
P = 0.002).
The mean aspartate aminotransferase (AST) value was
significantly higher in patients receiving sirolimus at
Month 6. However, all values of individual patients re-
mained below the 2-fold upper limit of the normal range
in either group. The mean alanine aminotransferase and
gamma-glutamyltransferase values were similar in both
groups.
Sirolimus is known to cause hyperlipidaemia. The mean
cholesterol, low-density lipoprotein (LDL), high-density
lipoprotein (HDL) and triglyceride levels did not differ sig-
nificantly among the groups (Figure 4). The ratio of LDL
to HDL cholesterol was also similar among the groups. Al-
though sirolimus treatment was associated with a tendency
to higher values of triglyceride and cholesterol, the range of
values and numbers of patients above the pre-defined cut-
offs were similar in both groups at Month 6. One patient
started a statin treatment in the sirolimus group and none
in the standard group.
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Table 3. Relevant clinical and laboratory data at Month 6a.
Sirolimus Standard
Parameter (N = 25) (N = 25) P-value
BMI (kg/m2)
Mean ± SD 24 ± 4 25 ± 3 0.314
Range 18–30 17–35
Systolic blood pressure (mmHg)
Mean ± SD 126 ± 15 134 ± 12 0.054
Range 96–156 103–160
Diastolic blood pressure (mmHg)
Mean ± SD 83 ± 8 85 ± 9 0.505
Range 60–101 70–102 0.702
Antihypertensive treatment, No. (%)
All 15 (60) 15 (60) 1.000
ACEi and/or ARB therapy 14 (56) 14 (56) 1.000
Diuretics 3 (12) 5 (20)
Others 3 (12) 3 (12) 1.000
Haemoglobin (g/l)
Mean ± SD 139.4 ± 8.49 144.2 ± 11.19 0.097
Range 118–154 128–166
MCV (fl)
Mean ± SD 82.40 ± 3.81 84.12 ± 4.47 0.005
Range 77.80–92.50 71.00–94.40
MCH (pg/cell)
Mean ± SD 28.88 ± 0.64 30.25 ± 1.91 0.009
Range 26.50–32.60 23.60–32.50
MCHC (g/dl)
Mean ± SD 35.04 ± 2.15 35.24 ± 1.34 0.465
Range 32.10–36.90 33.20–37.20
Leukocyte count (×103/mm3)
Mean ± SD 6.03 ± 2.06 5.81 ± 1.64 0.673
Range 3.0–12.2 3.9–12.2
Platelet count (×103/mm3)
Mean ± SD 253.7 ± 63.11 253.3 ± 53.70 0.981
Range 146.0–380.0 172.0–386.0
AST (U/l)
Mean ± SD 30.28 ± 8.54 24.92 ± 4.76 0.010
Range 19–53 17–36
Number of patients 0 0
>2 × ULN
ALT (U/l)
Mean ± SD 33.96 ± 25.79 26.36 ± 14.90 0.109
Range 9–114 12–71
Number of patients 1 0
>2 × ULN
Cholesterol (mmol/l)
Mean ± SD 4.94 ± 1.19 4.52 ± 0.84 0.147
Range 3.4–8.5 3.1–7.1
Number of patients ≥6.2 4 1
LDL cholesterol (mmol/l)
Mean ± SD 2.89 ± 1.01 2.66 ± 0.65 0.357
Range 1.6–6.1 1.4–4.6
Number of patients ≥4.1 3 1
HDL cholesterol (mmol/l)
Mean ± SD 1.40 ± 0.36 1.30 ± 0.36 0.331
Range 0.8–2.1 0.7–1.9
Number of patients ≤1 4 5
Triglyceride (mmol/l)
Mean ± SD 1.43 ± 0.86 1.24 ± 0.56 0.345
Range 0.5–3.4 0.4–2.7
Number of patients ≥4.5 0 0
aBMI, body mass index; MCV, mean corpuscular volume; MCH, mean
corpuscular haemoglobin; MCHC, mean corpuscular haemoglobin con-
centration; ALT, alanine aminotransferase; AST, aspartate aminotrans-
ferase; LDL, low-density lipoprotein; HDL, high-density lipoprotein;
ULN, upper limit of normal range.
Adverse events
Table 4 lists the adverse events. All patients reported at
least one adverse event during the 6 months in both groups.
No grade 3 or 4 events were reported. The incidence of
any infection was similar in the sirolimus group (80%)
and the standard group (88%). The most frequent infec-
tion was upper respiratory infection, and its incidence was
also similar in the sirolimus group (64%) and in the stan-
dard group (80%). No clinically significant opportunis-
tic infections were reported. Headache was more common
among patients receiving sirolimus (48%) than among pa-
tients of the standard group (12%). The total number of
patients with gastrointestinal adverse events was higher
in the sirolimus group (84%) than in the standard group
(32%). The most common gastrointestinal adverse events
were mucositis (72% of the sirolimus group versus 16%
of the standard group, P = 0.0001) and diarrhoea (36%
of the sirolimus group versus 20% of the standard group,
P = 0.345). A total of 48% patients in the sirolimus group
had adverse events leading to sirolimus dose reduction,
namely mucositis (16%), tooth extraction (8%), acne (4%),
sirolimus trough level >10 µg/l (4%), infection (4%), leu-
copenia (4%) and surgery (4%).
Discussion
Sirolimus is an immunosuppressant drug with strong anti-
proliferative properties. It has been approved for the pre-
vention of rejection after kidney and liver transplantation
and is used in combination with other immunosuppressive
drugs. The favourable effect of sirolimus in rodent mod-
els for ADPKD has prompted the initiation of clinical trials
testing the efficacy of sirolimus in halting PKD progression.
The potential risks of a sirolimus treatment have limited its
use in transplantation and may hamper a potential therapeu-
tic application in ADPKD patients. In this trial, however,
we show that sirolimus at doses of 1–2 mg/day was well
tolerated and safe in ADPKD patients.
There have been reports of nephrotoxicity and protein-
uria related to sirolimus use in solid organ transplant re-
cipients. Studies have shown an increase in urinary protein
excretion in patients converted from calcineurin inhibitor-
based therapy to sirolimus therapy as well as with de
novo use of sirolimus [15–17]. The origin of sirolimus-
associated urinary protein excretion, i.e. glomerular versus
tubular origin, is still a subject of investigations. How-
ever, the facts that proteinuria associated with the use
of sirolimus is mainly composed of albumin and, ACEi
effectively reduce sirolimus induced proteinuria support
the hypothesis that mTOR inhibitors increase glomerular
permeability [18]. In addition to albuminuria, glomeru-
lar proteinuria is characterized by increased excretion of
transferrin and IgG, two glomerular markers with differ-
ent molecular weights, which allow us to distinguish se-
lective from unselective proteinuria [19]. We analysed in
detail the urinary protein excretion in 24-h urine collec-
tions and found unchanged levels of albumin, transfer-
rin and IgG. Furthermore, the urinary excretion of the
low-molecular weight proteins α1-microglobulin and RBP,
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Fig. 4. Cholesterol (A) and triglyceride (B) levels were similar in both groups at baseline and at 6 months follow-up. The box indicates 50% of the
observed data points between the 1st and 3rd quartiles. The line within the box represents the median. The whiskers show the data between the 10th
and 90th percentiles.
characterizing tubular proteinuria [20], was unchanged by
sirolimus treatment. Together, these data reveal that albu-
minuria is minimal in young patients affected by ADPKD.
The mild albuminuria that is seen in some patients results
from glomerular leaking. Sirolimus at a dosage between 1
and 2 mg/day did not significantly deteriorate glomeru-
lar proteinuria, or induce tubular proteinuria. Since a
6-month treatment with sirolimus also did not impair the
GFR, sirolimus appears to have an excellent renal safety
profile in ADPKD patients.
In two randomized, double-blind multicentre studies, the
safety and efficacy of sirolimus compared with azathioprine
(Study 1) [21] or placebo (Study 2) [22] in combination with
cyclosporine and prednisone for the prevention of rejection
after renal transplantation were examined. These studies
compared the dose of 2 mg or 5 mg of sirolimus per day.
For the dose of 2 mg/day, the following side effects com-
pared to the control group were seen more frequently: hy-
percholesterolaemia, hypertriglyceridaemia, hypertension,
thrombocytopenia, acne and skin rash. All side effects oc-
curred in comedication with cyclosporine and prednisone.
We found unchanged lipid levels, although there is abun-
dant evidence that sirolimus causes an increase in serum
triglyceride levels and in the levels of cholesterol, LDL
and HDL [23]. In our current study, sirolimus treatment
was associated with a tendency to higher values of choles-
terol, LDL and triglyceride. These changes did not reach
statistical significance, most probably due to type II error.
Metabolic balance studies have also shown that the defect
in lipid metabolism is largely dose dependent [24].
The leukocyte and platelet counts remained unchanged.
However, we noted a mild but significant reduction of ery-
throcyte volume in patients treated with sirolimus. Several
studies with sirolimus in differently combined immuno-
suppressive regimen as well as one study with the sirolimus
derivate everolimus as a monotherapy have reported re-
duced MCV and microcytosis in solid organ transplant re-
cipients [25–29]. The aetiology of the reduced MCV is
not well understood. In these previous studies, patients re-
ceived concomitant immunosuppressive medication to pre-
vent organ rejection, iron supplementation and erythro-
poietin stimulation agents for the treatment of anaemia,
and many patients had impaired kidney function, factors
that may influence the morphological characteristic of ery-
throcytes. In our current study, we are able to ascribe this
sirolimus-associated effect on MCV and MCH to the drug
itself. These changes occurred at a low sirolimus trough
level and were not accompanied by a decrease of leuko-
cyte, platelet or red blood cell count, and are therefore
not attributable to the well-known anti-proliferative effect
of sirolimus on bone marrow colony-forming cells. Our
finding of a disproportionately low MCV in comparison
with unchanged red blood cell count suggests a defect in
the globin synthesis. The globin protein synthesis is under
tight control of eukaryotic initiation factor 2 (eIF2), and
the phosphorylation of eIF2α prevents translation initiation
and hence the synthesis of globin. As rapamycin causes an
increase in phosphorylation of eIF2α, we speculate that the
decrease in erythrocyte volume and haemoglobin content
seen in our patient is due to reduced globin synthesis rather
than an impaired red blood cell production [30,31].
Adverse events were transient and mild and no serious
adverse events occurred in our study. The incidence of in-
fections was similar in both groups, whereas oral ulcers
and headache occurred more frequently among patients
receiving sirolimus compared to patients receiving stan-
dard care. Oral adverse events, usually involving superficial
ulcerations of the gingival and buccal mucosa and tongue,
named aphthous mouth ulcers, have been reported in pa-
tients receiving sirolimus. Aphthous mouth ulcers occurred
in 10–19% of patients receiving sirolimus in phase III clin-
ical trials [21,22] and in up to 32% of patients switched
from a calcineurin inhibitor therapy to sirolimus [32]. No-
tably, the comedication with corticosteroids may decrease
the risk of sirolimus-associated aphthous mouth ulcers. In
a cohort of patients converted to sirolimus in the absence of
corticosteroids, a high incidence (up to 60%) was reported
for this complication [33]. We found a 72% incidence of
aphthous mouth ulcers among ADPKD patients treated
with sirolimus. Various hypotheses concerning the cause
of these ulcers have been generated without clear evidence.
The strong anti-proliferative properties of sirolimus might
function as the primary trigger for the development of these
ulcers, and the absence of corticosteroids may hamper their
secondary healing. Additionally, the true incidence of this
adverse event might be underestimated as these mucosal
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Table 4. Adverse events in the safety population from Month 0 to Month 6a
Number of patients (%)
Category Sirolimus (N = 25) Standard (N = 25) Total (N = 50) P-value
Any category 25 (100) 25 (100) 25 (100) 1.000
Infection
Total 20 (80) 22 (88) 42 (84) 0.702
Upper respiratory infection, sinusitis or bronchitis 16 (64) 20 (80) 36 (72) 0.345
Urinary tract infection or pyelonephritis 4 (16) 2 (8) 6 (12) 0.667
Pharyngitis 3 (12) 2 (8) 5 (10) 1.000
Perioral 2 (8) 0 2 (4) 0.490
Pain
Total 18 (72) 19 (76) 37 (74) 1.000
Flank pain 7 (28) 11 (44) 18 (36) 0.377
Headache 12 (48) 3 (12) 15 (30) 0.012
Muscoloskeletal 7 (28) 8 (32 15 (30) 1.000
Abdominal 3 (12) 2 (8) 5 (10) 1.000
Genital 2 (8) 1 (4) 3 (6) 1.000
Gastrointestinal
Total 21 (84) 8 (32) 29 (58) 0.0004
Aphthous ulcer or mucositis 18 (72) 4 (16) 22 (44) 0.0001
Diarrhoea 9 (36) 5 (20) 14 (28) 0.345
Teeth 2 (8) 0 2 (4) 0.490
Heartburn 2 (8) 1 (4) 3 (6) 1.000
Nausea 3 (12) 0 3 (6) 1.000
Skin related
Total 13 (52) 10 (40) 23 (46) 0.571
Acne 13 (52) 7 (28) 20 (40) 0.148
Folliculitis 1 (4) 2 (8) 3 (6) 1.000
Pulmonary or upper respiratory
Cough 6 (24) 1 (4) 7 (14) 0.098
Renal or genitourinary
Macrohaematuria 1 (4) 4 (16) 5 (10) 0.349
Lymphatics
Limb oedema 3 (12) 0 3 (6) 0.235
Neurologic
Dizziness 3 (12) 0 3 (6) 0.235
Blood and bone marrow
Leucopenia 2 (8) 0 2 (4) 0.490
Sexual or reproductive function
Irregular menses 2 (8) 0 2 (4) 0.490
aTable shows number of patients (percent). Adverse events affecting ≥5% in either group were described and graded according to the National Cancer
Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.
lesions can easily be mistaken for herpes simplex infection
[34]. The incidence of headache was higher in patients re-
ceiving sirolimus. Thus far headaches were not known side
effects of sirolimus treatment. Our finding has recently been
validated by analysing pharmacovigilance data in other pa-
tient populations. As a consequence, the product informa-
tion is being adapted on a worldwide basis to include this
information.
A limitation of our study is the low number of patients and
the short time of follow-up. Therefore, we cannot exclude
the occurrence of rare adverse events or events occurring
only after long-term treatment. However, based on experi-
ence in other patient populations treated with sirolimus, we
anticipated that we could detect major side effects/adverse
events in the sirolimus-treated patients with sufficient ro-
bustness in a relatively homogeneous ADPKD population
in a 6-month time interval.
In conclusion, this short-term analysis reveals that
sirolimus treatment is safe for ADPKD patients when the
drug is used at a dosage between 1 and 2 mg/day. Treat-
ment adherence was excellent, the renal safety profile was
encouraging and the characteristic side effects of sirolimus
were well manageable. The Data Safety Monitoring Board
(DSMB) has therefore recommended continuation of the
study. The upcoming efficacy data of this trial will estab-
lish whether sirolimus has a beneficial effect on the re-
lentlessly progressive cyst volume growth in patients with
ADPKD.
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